|
FAM54B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.61619972749838E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.50499954113081E-10 |
| Normal-vs-Stage2 |
2.812400E-01 |
| Normal-vs-Stage3 |
3.79319908816456E-11 |
| Normal-vs-Stage4 |
3.35990124611385E-11 |
| Stage1-vs-Stage2 |
1.299820E-03 |
| Stage1-vs-Stage3 |
9.223900E-03 |
| Stage1-vs-Stage4 |
6.276100E-03 |
| Stage2-vs-Stage3 |
2.23259999998504E-06 |
| Stage2-vs-Stage4 |
1.60319999999992E-05 |
| Stage3-vs-Stage4 |
5.821200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.77875508661418E-12 |
| Normal-vs-AfricanAmerican |
1.599490E-04 |
| Normal-vs-Asian |
4.28520000039789E-07 |
| Caucasian-vs-AfricanAmerican |
6.994200E-01 |
| Caucasian-vs-Asian |
5.323400E-01 |
| AfricanAmerican-vs-Asian |
9.524600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.28750000345002E-08 |
| Normal-vs-Female |
7.19269976912074E-10 |
| Male-vs-Female |
8.331800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.74190004034836E-10 |
| Normal-vs-Age(41-60Yrs) |
5.43430000998768E-09 |
| Normal-vs-Age(61-80Yrs) |
1.69169999999497E-05 |
| Normal-vs-Age(81-100Yrs) |
1.591560E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.279200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.876000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.768400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.147000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.831600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.329800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.54869491967247E-11 |
| Classical-VS-Follicular |
2.72004641033163E-14 |
| Classical-VS-Other |
6.627200E-01 |
| Classical-VS-Normal |
2.51532128459075E-12 |
| Tall-VS-Follicular |
<1E-12 |
| Tall-VS-Other |
2.035800E-02 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
4.854300E-02 |
| Follicular-VS-Normal |
4.666800E-01 |
| Other-VS-Normal |
1.000290E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.66539999971683E-07 |
| Normal-vs-N1 |
4.56412685423402E-13 |
| N0-vs-N1 |
4.16589999999717E-05 |
|
|
